SWM
GSK icon

SeaCrest Wealth Management’s GSK GSK Stock Holding History

SeaCrest Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,918
Closed -$211K – 628
2024
Q1 		$211K Sell
4,918
-1,674
-25% -$69K 0.03% 553
2023
Q4 		$258K Sell
6,592
-19,532
-75% -$701K 0.03% 500
2023
Q3 		$947K Buy
26,124
+673
+3% +$23.9K 0.12% 175
2023
Q2 		$907K Sell
25,451
-1,770
-7% -$63.5K 0.11% 186
2023
Q1 		$969K Buy
27,221
+1,273
+5% +$44.5K 0.13% 176
2022
Q4 		$912K Sell
25,948
-1,588
-6% -$52.9K 0.13% 183
2022
Q3 		$810K Buy
+27,536
New +$1.04M 0.12% 184
2022
Q2 		– Sell
-32,794
Closed -$1.79M – 1628
2022
Q1 		$1.79M Sell
32,794
-364
-1% -$19.8K 0.21% 99
2021
Q4 		$1.83M Sell
33,158
-10,529
-24% -$548K 0.2% 96
2021
Q3 		$2.09M Buy
43,687
+15,698
+56% +$788K 0.25% 76
2021
Q2 		$1.39M Buy
27,989
+1,201
+4% +$57.7K 0.17% 123
2021
Q1 		$1.2M Sell
26,788
-1,767
-6% -$80.2K 0.16% 136
2020
Q4 		$1.31M Sell
28,555
-4,935
-15% -$227K 0.18% 117
2020
Q3 		$1.58M Sell
33,490
-340
-1% -$17K 0.25% 86
2020
Q2 		$1.73M Buy
33,830
+2,458
+8% +$126K 0.3% 73
2020
Q1 		$1.49M Sell
31,372
-943
-3% -$50.3K 0.32% 72
2019
Q4 		$1.9M Buy
32,315
+4,749
+17% +$264K 0.32% 71
2019
Q3 		$1.47M Buy
27,566
+1,560
+6% +$80.3K 0.28% 82
2019
Q2 		$1.3M Buy
26,006
+1,316
+5% +$66K 0.26% 84
2019
Q1 		$1.29M Buy
24,690
+1,140
+5% +$57K 0.22% 96
2018
Q4 		$1.13M Buy
23,550
+11,572
+97% +$570K 0.23% 90
2018
Q3 		$601K Buy
11,978
+312
+3% +$15.9K 0.1% 217
2018
Q2 		$588K Buy
11,666
+680
+6% +$34.2K 0.11% 214
2018
Q1 		$537K Buy
10,986
+1,915
+21% +$89.2K 0.1% 226
2017
Q4 		$402K Buy
+9,071
New +$419K 0.07% 293

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

SeaCrest Wealth Management's GSK Position: Q2 2024 in Review

SeaCrest Wealth Management sold out of GSK (GSK) in Q2 2024, closing a stake of 4,918 shares — an estimated $211K sold.

SeaCrest Wealth Management first reported a position in GSK in Q4 2017 and held it in 25 quarters. The position peaked at $2.09M in Q3 2021. 884 funds tracked by Wall St. Rank hold GSK as of Q2 2024.

  • SeaCrest Wealth Management reported no remaining GSK position as of Q2 2024 after selling out during the quarter.
  • SeaCrest Wealth Management sold 4,918 GSK shares in Q2 2024, an estimated $211K.
  • SeaCrest Wealth Management first reported a position in GSK in Q4 2017 and held it in 25 quarters.
  • SeaCrest Wealth Management's GSK position peaked at $2.09M in Q3 2021.
  • 884 funds tracked by Wall St. Rank held GSK as of Q2 2024.

Based on SeaCrest Wealth Management's 13F filing for Q2 2024, filed 22 Jul 2024.